

Changes in SynAct Pharma's Nomination Committee ahead of the 2024 Annual General Meeting

SynAct Pharma's Nomination Committee for the 2024 Annual General Meeting was announced in a press release on November 22, 2023. As a result of the appointment of new Board members, following a resolution by the Extra General Meeting on March 20, 2024, the composition of the Nomination Committee has changed. Henrik Stage replaces Anders Kronborg as representative for Goodwind Holding GmbH. Anders Kronborg will remain on the Nomination Committee in his capacity as Chairman of the Board of SynAct Pharma, replacing the previous Chairman of the Board in the Nomination Committee.

The Nomination Committee for the 2024 Annual General Meeting will thereafter consist of the following members:

- Niels Ankerstjerne Sloth, Chairman of the Nomination Committee, appointed by Bioinvest Aps
- Per Colleen, appointed by TomEnterprise Public Capital AB
- Henrik Stage, appointed by Goodwind Holding GmbH
- Anders Kronborg, Chairman of the Board of Directors

The Nomination Committee's proposed items will be presented in the notice convening the Annual General Meeting and on SynAct's web site. SynAct Pharma's Annual General Meeting 2024 will be held on Friday, May 31, 2024.

For further information, please contact:

Björn Westberg

CFO, SynAct Pharma AB

Phone: +46 73 394 09 53

Mail: bwe@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com.

Attachments

[Changes in SynAct Pharma's Nomination Committee ahead of the 2024 Annual General Meeting](#)